#JPM22 - Dealmaking in 2022: What's Big Pharma looking for and what is it willing to pay?
Okay, well, thanks everybody for coming out today. We had a ton of registrations for this panel discussion about dealmaking in 2022. I think that every year is a big year when it comes to dealmaking, M&A, and business development deals. And we’re certainly seeing a lot of interest this year, particularly after a very interesting 2021 — set the stage for a lot of people looking at where they’re at in terms of strategy, and how they position their company going into the new year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.